For patients with severe mental illness, a smartphone intervention is highly usable and acceptable and improves outcomes.
Your search for major depressive disorder returned 77 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Universal school-based MDD screening increases identification of adolescents with MDD symptoms and initiation of treatment.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Acceptability of a passive smartphone-based ecological momentary assessment (EMA) app is relatively low among individuals with schizophrenia spectrum disorders.
This was a study protocol for a phase II pilot feasibility study that will assess the feasibility of ketamine for depression in patients with advanced life-limiting illnesses.
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
Suicidal ideation, plan, and attempt in young U.S. adults increased from 2008-2009 to 2018-2019 after controlling for MDE, cannabis use, and CUD.
Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Researchers compared how patients experiencing a major depressive episode and control participants perceived contrast patterns.
For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses